SCHEMBL12654627

SCHEMBL12654627

CN1C(=O)CN(C(=O)Nc2ncn[nH]2)c2nc(-c3cccc(C(F)(F)F)c3)ccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PHGDH O43175 1/20 0.40
▸ SIRT2 Q8IXJ6 1/20 0.38
▸ TRPA1 O75762 1/20 0.37
▸ KMO O15229 2/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ ALPL P05186 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ DGAT2 Q96PD7 2/20 0.35
▸ CNR2 P34972 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ PIK3CD O00329 1/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ PIK3CG P48736 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16563448 0.85 KMO (0.41) TRPA1KMOCNR2CNR1FYN
SCHEMBL16563376 0.84 TRPA1 (0.37) TRPA1KMOCNR2CNR1FYN
SCHEMBL12958992 0.84 HTR2C (0.41) TRPA1KMOCNR2CNR1FYN
SCHEMBL12958983 0.84 MPL (0.44) TRPA1KMOCNR2CNR1FYN
SCHEMBL12654628 0.83 CA2 (0.42) PHGDHTRPA1KMOCNR2CNR1
SCHEMBL1815198 0.82 EGFR (0.41) SIRT2TRPA1KMOCNR2CNR1
SCHEMBL12654391 0.82 KMO (0.41) TRPA1KMODGAT2CNR2CNR1
SCHEMBL16563456 0.82 ALOX15 (0.46) SIRT2TRPA1KMOCNR2CNR1
SCHEMBL16563664 0.81 TRPA1 (0.40) TRPA1KMOMEN1KMT2ACNR2
SCHEMBL12958986 0.81 SCN9A (0.39) SIRT2TRPA1KMOKMT2ACNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9556201-B2 Bicyclic pyridines and analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-01-31 — — US disclosed
US-9556201-B2 Bicyclic pyridines and analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-01-31 — — US disclosed
EP-2493888-B1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-04-06 — — EP disclosed
US-20120252780-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2012-10-04 — — US disclosed
WO-2011059839-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2011-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252780-A1 BICYCLIC PYRIDINES AND ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 PHGDH 1399/4885SIRT2 3/4885TRPA1 2822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback